Table 4.
HRs for Death Resulting From Breast Cancer According to Race/Ethnicity (non-Hispanic black v non-Hispanic white) and Tumor Subtype
| Race/Ethnicity | No. of Deaths | Model One* |
Model Two† |
Model Three‡ |
Model Four§ |
||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||
| ER positive | |||||||||
| White (reference) | 439 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 74 | 2.28 | 1.78 to 2.93 | 1.91 | 1.47 to 2.48 | 1.58 | 1.21 to 2.05 | 1.62 | 1.24 to 2.12 |
| ER positive (0 to 2 years) | |||||||||
| White (reference) | 102 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 24 | 3.73 | 1.92 to 7.26 | 3.14 | 1.61 to 6.14 | 2.53 | 1.29 to 4.93 | 2.65 | 1.34 to 5.24 |
| ER positive (≥ 2 years to end of follow-up) | |||||||||
| White (reference) | 337 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 50 | 2.13 | 1.62 to 2.79 | 1.77 | 1.34 to 2.35 | 1.46 | 1.11 to 1.94 | 1.50 | 1.12 to 2.00 |
| ER negative | |||||||||
| White (reference) | 456 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 92 | 1.38 | 1.10 to 1.73 | 1.19 | 0.94 to 1.51 | 1.14 | 0.90 to 1.45 | 0.99 | 0.77 to 1.28 |
| Luminal A like | |||||||||
| White (reference) | 162 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 22 | 2.50 | 1.60 to 3.93 | 1.98 | 1.24 to 3.16 | 1.78 | 1.12 to 2.86 | 1.76 | 1.09 to 2.85 |
| Luminal B like | |||||||||
| White (reference) | 285 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 55 | 1.79 | 1.34 to 2.41 | 1.60 | 1.18 to 2.19 | 1.58 | 1.16 to 2.15 | 1.56 | 1.14 to 2.15 |
| Triple negative | |||||||||
| White (reference) | 304 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 72 | 1.41 | 1.09 to 1.84 | 1.22 | 0.92 to 1.60 | 1.04 | 0.79 to 1.37 | 1.04 | 0.79 to 1.37 |
| HER2 type | |||||||||
| White (reference) | 121 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Black | 16 | 1.15 | 0.68 to 1.95 | 1.04 | 0.60 to 1.79 | 1.00 | 0.57 to 1.73 | 0.99 | 0.57 to 1.73 |
Abbreviation: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio.
Age adjusted: age at diagnosis, National Comprehensive Cancer Network center, and year of diagnosis.
Model one plus socioeconomic factors: insurance type, educational attainment, employment status, menopausal status, comorbidity score, and body mass index.
Model two plus tumor characteristics: stage at diagnosis, triggering event, tumor grade (included in all subtype models except for luminal A like and luminal B like), progesterone receptor status (included in ER-positive and ER-negative models only), and HER2 status.
Model three plus treatment: chemotherapy, hormonal therapy (included in all models except for triple-negative and HER2-type models), and trastuzumab use (included in luminal B–like and HER2-type models only).